{"id":"insulin-lispro-u100","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":{"chemblId":"CHEMBL1201538","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Insulin lispro is a recombinant human insulin analog with a modified amino acid sequence that allows faster absorption and onset of action compared to regular human insulin. It binds to the insulin receptor on muscle, fat, and liver cells, facilitating glucose transport into cells and promoting glycogen synthesis while inhibiting gluconeogenesis. This rapid action makes it suitable for mealtime insulin therapy in diabetes management.","oneSentence":"Insulin lispro is a rapid-acting insulin analog that binds to insulin receptors on cells to promote glucose uptake and utilization for blood sugar control.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:16:20.730Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT05834868","phase":"PHASE3","title":"Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tonghua Dongbao Pharmaceutical Co.,Ltd","startDate":"2022-05-06","conditions":"Type 2 Diabetes","enrollment":1040},{"nctId":"NCT07282054","phase":"PHASE3","title":"Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes","status":"COMPLETED","sponsor":"Tonghua Dongbao Pharmaceutical Co.,Ltd","startDate":"2022-04-13","conditions":"Type 1 Diabetes","enrollment":550},{"nctId":"NCT07090824","phase":"PHASE1","title":"Subcutaneous Pharmacokinetic Evaluation of Monomeric Insulin and Lyumjev in Adults With Type 1 Diabetes","status":"RECRUITING","sponsor":"Stanford University","startDate":"2025-10-28","conditions":"Diabetes Mellitus, Type 1, Type 1 Diabetes Mellitus","enrollment":20},{"nctId":"NCT05462756","phase":"PHASE3","title":"A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2022-08-11","conditions":"Type 2 Diabetes, Type 2 Diabetes Treated With Insulin","enrollment":730},{"nctId":"NCT04537923","phase":"PHASE3","title":"A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-10-19","conditions":"Type 2 Diabetes","enrollment":1428},{"nctId":"NCT02688933","phase":"PHASE4","title":"A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-05-05","conditions":"Type 1 Diabetes Mellitus","enrollment":638},{"nctId":"NCT03495908","phase":"NA","title":"Regular Insulin vs Rapid Insulin Delivered by V-Go","status":"COMPLETED","sponsor":"East Coast Institute for Research","startDate":"2018-04-09","conditions":"Type 2 Diabetes, Type 2 Diabetes Mellitus","enrollment":136},{"nctId":"NCT04484779","phase":"NA","title":"A Study of an Insulin Management System in Participants With Type 1 or Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-07-14","conditions":"Type 1 Diabetes, Type 2 Diabetes","enrollment":67},{"nctId":"NCT03334448","phase":"PHASE1","title":"A Study to Compare 2 Formulations of LY900014 in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-12-04","conditions":"Healthy","enrollment":49},{"nctId":"NCT03616977","phase":"PHASE1","title":"Study to Compare 2 Formulations of LY900014 in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2018-08-03","conditions":"Healthy","enrollment":69},{"nctId":"NCT03214380","phase":"PHASE3","title":"A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-07-14","conditions":"Type 2 Diabetes Mellitus","enrollment":933},{"nctId":"NCT04235439","phase":"PHASE1","title":"PK/PD Biosimilarity Study of Gan & Lee Insulin Lispro Injection vs. EU and US Humalog® in Healthy Males","status":"COMPLETED","sponsor":"Gan and Lee Pharmaceuticals, USA","startDate":"2019-04-23","conditions":"Diabetes Mellitus","enrollment":36},{"nctId":"NCT04100473","phase":"PHASE2","title":"Dose Response of Dance 501 in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Dance Biopharm Inc.","startDate":"2018-04-23","conditions":"Type 2 Diabetes Mellitus","enrollment":24},{"nctId":"NCT03307512","phase":"PHASE2","title":"PK and PD Profile of Dance 501 in Healthy, Non-diabetic Subjects With Mild to Moderate Asthma or COPD","status":"TERMINATED","sponsor":"Dance Biopharm Inc.","startDate":"2018-02-06","conditions":"Safety and Tolerability","enrollment":40},{"nctId":"NCT02500979","phase":"PHASE1","title":"Effect of a Fixed Pramlintide: Insulin Dose Ratio on Postprandial Glucose in Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-08-17","conditions":"Type 1 Diabetes Mellitus","enrollment":34},{"nctId":"NCT02197520","phase":"PHASE1","title":"A Study To Compare the Effects of Insulin Peglispro and Glargine on Insulin Sensitivity and Meal Time Insulin Requirements in Type 2 Diabetics","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2014-07","conditions":"Diabetes Mellitus, Type 2","enrollment":24},{"nctId":"NCT01067118","phase":"PHASE2","title":"A Randomized Control Trial Comparing Linjeta Versus Humalog in Pumps: Effect on Postprandial Blood Sugars.","status":"WITHDRAWN","sponsor":"Stanford University","startDate":"2010-04","conditions":"Diabetes Mellitus","enrollment":""},{"nctId":"NCT02562326","phase":"PHASE1","title":"A Trial to Investigate the Efficacy, Pharmacokinetics, Safety and Tolerability of BioChaperone Insulin Lispro in Comparison to Humalog® U-100 in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Adocia","startDate":"2015-09","conditions":"Type 2 Diabetes Mellitus","enrollment":51},{"nctId":"NCT02528396","phase":"PHASE1","title":"To Investigate the Efficacy and Safety of Individualized Doses of BioChaperone Insulin Lispro in Comparison to Humalog® U-100 in Patients With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Adocia","startDate":"2015-08","conditions":"Type 1 Diabetes Mellitus","enrollment":36},{"nctId":"NCT02529293","phase":"PHASE1","title":"A Clinical Trial Investigating the Intra-subject Variability of Pharmacokinetics and Glucodynamics of BioChaperone Insulin Lispro U-100 Product and U-200 Product in Healthy Volunteers","status":"COMPLETED","sponsor":"Adocia","startDate":"2015-08","conditions":"Healthy","enrollment":26},{"nctId":"NCT02111083","phase":"PHASE1","title":"A Study of 2 Different Formulations of Insulin Lispro in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2014-05","conditions":"Healthy Volunteers","enrollment":38}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":28,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Humalog","LY275585"],"phase":"phase_3","status":"active","brandName":"Insulin Lispro (U100)","genericName":"Insulin Lispro (U100)","companyName":"Eli Lilly and Company","companyId":"eli-lilly-and-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Insulin lispro is a rapid-acting insulin analog that binds to insulin receptors on cells to promote glucose uptake and utilization for blood sugar control. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}